MBX Biosciences (MBX) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, gaining 245.2% versus a loss of 10.4%. MBX Biosciences is the larger company by market cap ($2.54 billion vs $2.46 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | SUPN |
|---|---|---|
| Share price | $52.71 | $42.20 |
| Market cap | $2.54B | $2.46B |
| 1-day change | -3.36% | -1.97% |
| YTD return | +72.92% | -13.38% |
| 1-year return | +245.19% | -10.44% |
| 5-year return | — | +35.98% |
| Forward P/E | — | 9.46 |
| EPS (TTM) | $-2.37 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $718.95M |
| Revenue growth (YoY) | — | +8.63% |
| Net income (latest FY) | $-87.00M | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | — | -8.66% |
| Net margin | — | -5.36% |
| 52-week high | $72.64 | $59.68 |
| 52-week low | $12.94 | $40.51 |
| Distance from 52-week high | -27.44% | -29.29% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +78.90% | +46.33% |
| Average volume | 539.34K | 766.52K |
| Shares outstanding | 48.16M | 58.22M |
| Employees | 63 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed SUPN by 255.6 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
MBX vs SUPN FAQ
Which is bigger, MBX Biosciences or Supernus Pharmaceuticals?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.54B compared with $2.46B for Supernus Pharmaceuticals (SUPN).
Which stock has performed better over the past year, MBX or SUPN?
MBX returned +245.19% over the past 12 months, compared with -10.44% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.